New Insights into Glioblastoma Treatment for Older Adults Patients
8 Oct 2024
Brussels, Belgium, 8 October 2024. A groundbreaking study1 led by Dr Monika E. Hegi, MD, PhD and European Organisation for Research and Treatment of Cancer (EORTC) headquarters team (Felix Oppong Msc, Dr Thierry Gorlia, PhD) reveals that older adults glioblastoma patients with truly unmethylated MGMT promoter do not benefit from temozolomide (TMZ) treatment, challenging current treatment protocols and paving the way for more personalised therapies.
The study reanalysed data from the CE.6 and pooled Nordic/NOA-08 trials, involving 687 patients, to assess the impact of MGMT promoter methylation on TMZ treatment efficacy. Using a specific cutoff established through a pooled analysis of four clinical trials, the research confirmed that patients with truly unmethylated MGMT promoter derived no benefit from TMZ, whether administered alone or in combination with radiotherapy (RT). This finding underscores the necessity of using validated MGMT promoter methylation assays to accurately identify patients who will not benefit from TMZ, thereby reducing unnecessary toxicity and allowing for the exploration of more promising treatment options.
The significance of this study lies in its potential to transform the treatment landscape for older adults glioblastoma patients. By accurately identifying patients who will not benefit from TMZ, healthcare providers can avoid undue toxicity and focus on more effective treatment strategies. The European Organisation for Research and Treatment of Cancer (EORTC) and other collaborating organisations emphasise the importance of stratified patient management to improve outcomes without compromising patient safety.
“This study represents a pivotal moment in the treatment of glioblastoma, particularly for our older adults patients,” says Monika E. Hegi, PhD. “By refining our approach to patient selection, we can significantly enhance treatment efficacy and patient quality of life.”
In conclusion, these findings highlight the critical role of MGMT promoter methylation in guiding treatment decisions for glioblastoma, offering a path toward more personalised and effective therapies.
About EORTC
The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.
Contact
Caroline Moulins
Head of Communications
caroline.moulins@eortc.org
Related News
EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients
5 Nov 2024
Pink October at EORTC: Over 60 years of impactful breast cancer research
29 Oct 2024
Spotlight on ENA 2024 News
25 Oct 2024
Do regulations and policies undermine the social value of independent academic research?
25 Oct 2024
EORTC Quality of Life Group’s participation to ISOQOL 2024
10 Oct 2024
TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival
24 Sep 2024
New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
17 Sep 2024
Late Breaking Results from the EORTC 1333/PEACE III phase III trial
16 Sep 2024
EORTC’s presence at ESMO 2024
10 Sep 2024
Meet the new EORTC Board
9 Jul 2024